Alterity Therapeutics Ltd has released a press release.
Annual Report to shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Prana to present PBT434 data at International Congress
- First Volunteers Dosed in Phase I Clinical Trial of PBT434
- Prana to commence Phase 1 clinical trial of PBT434
- PBT434 at the 6th International Multiple System Atrophy Conf
- Prana receives $3 million R&D Tax Incentive Refund
Later from Alterity Therapeutics
- New data show potential for PBT434 to treat MSA
- Life Bioscience LLC leads strategic investment upto A$44.5M
- Orphan Designation for PBT434 for treatment of MSA
- Prana receives A$3.3 million R&D Tax Incentive Refund
- Alterity presents initial Phase 1 clinical trial data at AAN
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics